Can I Take Vitamin B12 with Repatha (Evolocumab)?

The Short Answer: No Direct Interaction, But Context Matters

Repatha and vitamin B12 do not share a metabolic pathway. Evolocumab is a fully human monoclonal antibody that is cleared by proteolytic degradation, not by hepatic cytochrome P450 enzymes or renal tubular transporters. Vitamin B12 is absorbed via intrinsic factor in the terminal ileum and stored in the liver. These two substances simply do not compete for the same receptors, enzymes, or transporters.

The reason women ask this question matters, though. Many women prescribed Repatha also take metformin, either for type 2 diabetes or for PCOS. Metformin reduces intestinal absorption of vitamin B12 through a mechanism involving calcium-dependent membrane transporters in the ileum, and that depletion is the actual clinical story behind this search query.

How Repatha Works

Evolocumab is a PCSK9 inhibitor approved by the FDA for adults with heterozygous or homozygous familial hypercholesterolemia and for adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond what statins provide. It binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing that protein from tagging LDL receptors on hepatocytes for degradation. More LDL receptors on liver cells means more LDL-C cleared from blood. In the FOURIER trial, evolocumab reduced LDL-C by a median of 59% and cut major cardiovascular events by 15% versus placebo over a median follow-up of 2.2 years.

How Vitamin B12 Works

B12 (cobalamin) is a water-soluble vitamin that acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase. These reactions are central to DNA synthesis, myelin formation, and red blood cell production. Deficiency produces macrocytic anemia and peripheral neuropathy, and in women it can also affect mood and cognitive function in ways that overlap with perimenopause symptoms, making it easy to miss.

Why Women on Repatha Should Still Think About B12

The population most likely to be prescribed Repatha includes older women with established ASCVD or familial hypercholesterolemia, and a significant portion of those women also take metformin for concurrent type 2 diabetes or insulin resistance. This convergence creates a real but indirect concern.

The Metformin Connection

Metformin-induced B12 depletion is not a minor footnote. A cross-sectional analysis published in Diabetes Care found that B12 deficiency occurred in approximately 30% of patients on long-term metformin therapy. Deficiency was significantly associated with metformin dose and duration. Women with PCOS who start metformin in their 20s and continue into their 40s may enter perimenopause already B12-depleted without knowing it.

If you take metformin plus Repatha and your B12 is low, the neuropathy you notice in your hands and feet is not caused by Repatha. Repatha does not damage nerves. But a clinician who does not check your B12 may struggle to explain your symptoms, and the workup can drag on longer than necessary.

PCOS: The Life-Stage Where This Triple Overlap Is Most Common

Women with PCOS are prescribed metformin at high rates, with some estimates suggesting 35-50% of PCOS patients use metformin at some point in their care. PCOS also tracks with insulin resistance and dyslipidemia, so women who progress to overt type 2 diabetes or develop premature ASCVD risk may eventually qualify for Repatha on top of an existing metformin regimen. Checking B12 at baseline and annually is a simple, inexpensive protective step that most PCOS guidelines do not yet mandate explicitly.

Perimenopause and Postmenopause

Cardiovascular risk rises sharply after menopause. The loss of estrogen's favorable effects on LDL and HDL means many women encounter familial hypercholesterolemia diagnoses or frank ASCVD in their 50s and 60s for the first time. The American College of Cardiology and American Heart Association guidelines position PCSK9 inhibitors as second-line or third-line therapy after high-intensity statins, but postmenopausal women with very high baseline LDL or statin intolerance are genuine candidates.

Gastric acid production declines with age, and postmenopausal women on proton pump inhibitors (PPIs) for reflux face a secondary mechanism of B12 malabsorption because acid is required to cleave B12 from dietary protein. If you are postmenopausal, on a PPI, and starting Repatha, ask your clinician to check a serum B12 and methylmalonic acid (MMA) level at the same visit.

Reproductive Years: Trying to Conceive

Women of reproductive age who carry familial hypercholesterolemia and want to use Repatha should know that Repatha is contraindicated in pregnancy (see the dedicated pregnancy section below). B12 status is especially relevant here because B12 deficiency before conception increases the risk of neural tube defects and recurrent pregnancy loss, separate from any interaction with Repatha.

Pharmacokinetic Profile of Evolocumab: Why B12 Cannot Interact Directly

Understanding why there is no direct interaction requires a brief look at evolocumab's pharmacokinetics. Evolocumab is administered subcutaneously at 140 mg every two weeks or 420 mg once monthly. It is not a small molecule processed by CYP450 isoenzymes. Like other monoclonal antibodies, it is broken down by endosomal proteases into amino acids. It does not pass through the gut in any biologically active form, and it does not affect gastrointestinal absorptive transporters.

Vitamin B12's absorption depends on intrinsic factor secreted by gastric parietal cells, transport through the ileal cubam receptor complex, and hepatic uptake via transcobalamin receptors. None of these steps involve PCSK9, LDL receptors, or any pathway touched by evolocumab. A formal drug interaction analysis in the Repatha prescribing information does not list B12 among substances with known interactions, and no mechanism exists for one to develop.

The framework that helps clinicians sort this out: ask three questions before assuming any supplement-biologic interaction exists.

1. Do they share a metabolic enzyme or transporter?
2. Does either agent alter gastric pH or gut motility in a way that affects the other's absorption?
3. Do they compete for serum proteins or receptor binding?

For B12 and evolocumab, all three answers are no. The clinical concern shifts entirely to what else the patient is taking, particularly metformin, PPIs, or histamine-2 blockers.

Vitamin B12 Dosing, Forms, and What Women Actually Need

If your B12 is low or you are in a higher-risk category, the following practical information applies regardless of Repatha use.

Forms of B12

• Cyanocobalamin: synthetic, stable, widely available, converted to active forms in tissues. Adequate for most women.
• Methylcobalamin: active form, sometimes preferred for neurological symptoms, though evidence that it outperforms cyanocobalamin at equivalent doses is limited.
• Hydroxocobalamin: used in injectable repletion for severe deficiency.

Doses for Different Situations

For dietary supplementation in healthy premenopausal women, the recommended dietary allowance (RDA) is 2.4 mcg/day. During pregnancy the RDA rises to 2.6 mcg/day, and during lactation to 2.8 mcg/day. These low doses are achievable through food alone if you eat animal products.

For metformin-induced deficiency, oral doses of 1,000 mcg/day of cyanocobalamin are commonly used and have been shown in the HOME trial to normalize serum B12 in the majority of metformin users within three months. Intramuscular injection (1,000 mcg monthly) is reserved for pernicious anemia or documented malabsorption where oral therapy cannot work.

Timing Relative to Repatha Injections

Because there is no pharmacokinetic interaction, no dose separation between B12 and evolocumab injections is necessary. You may take oral B12 at any time. Evolocumab is injected subcutaneously at home using an autoinjector or prefilled syringe, and that schedule is independent of any oral supplement.

Pregnancy, Lactation, and Contraception

Repatha is contraindicated in pregnancy. This is not a precautionary labeling statement rooted in uncertainty alone. PCSK9 plays a role in fetal development, and cholesterol is required for fetal cell membrane synthesis and steroid hormone production. Animal studies in monkeys at doses that produced serum exposures approximately 12 times the human exposure at the maximum recommended dose showed no direct fetal toxicity, but the biological plausibility of harm from extreme LDL-C lowering during organogenesis warrants avoidance. Human data in pregnancy are absent.

Women of reproductive age who are prescribed evolocumab should use effective contraception throughout treatment. If you become pregnant while on Repatha, stop the medication immediately and contact your prescriber. The drug's half-life is approximately 11 to 17 days, so it clears over several weeks after the last dose.

Lactation: It is unknown whether evolocumab transfers into human breast milk. IgG antibodies do transfer into milk to some degree, but oral bioavailability of large proteins in an infant's gut is negligible. Because the maternal cardiovascular risk driving Repatha use is generally lower in the early postpartum period and because no safety data exist, most clinicians recommend deferring Repatha until breastfeeding is complete. Discuss the timing with your cardiologist or lipidologist.

Vitamin B12 in pregnancy and lactation: B12 is not only safe but essential. Deficiency during the first trimester is associated with neural tube defects and with gestational diabetes risk. Vegan and vegetarian women must supplement B12 actively during pregnancy. The prenatal vitamin you take should include at least 2.6 mcg of B12, and many prenatal formulas include substantially more without risk of toxicity.

Monitoring Plan: What to Check and When

If you are taking Repatha and considering vitamin B12 supplementation, the monitoring approach depends on your risk profile.

Low-Risk Profile

You take no metformin, eat animal products regularly, are under 50, and have no GI malabsorption history. In this case, routine B12 monitoring is not required beyond what your general annual labs may include. B12 supplementation at RDA levels is safe and unnecessary to track closely.

Higher-Risk Profile

You meet one or more of these criteria: metformin use (any dose), vegan or strict vegetarian diet, age over 50, long-term PPI use, prior gastric bypass or sleeve gastrectomy, history of pernicious anemia in a first-degree relative, or symptoms of neuropathy or unexplained fatigue. In this case:

• Check serum B12 and MMA at baseline before or shortly after starting Repatha.
• Recheck annually.
• If serum B12 is below 300 pg/mL (some labs use 200 pg/mL as the lower limit, but functional deficiency can occur up to 300 pg/mL), supplement with 1,000 mcg cyanocobalamin orally per day.
• If MMA is elevated with a low-normal serum B12, treat as deficiency regardless of the absolute B12 number.

A 2019 American Diabetes Association Standards of Medical Care guidance note recommends periodic B12 monitoring for patients on metformin, though it does not specify an interval. Annual testing is a reasonable minimum.

Conditions Where This Article Is Most Relevant

This overlap of Repatha plus B12 concern is most directly relevant in several female-specific conditions.

Familial Hypercholesterolemia in Women

Familial hypercholesterolemia (FH) affects approximately 1 in 250 people. Women with FH have a cardiovascular risk that is somewhat lower than men at equivalent LDL levels in their reproductive years, likely due to estrogen's protective effects, but that protection largely disappears after menopause. ACOG has noted that FH is frequently underdiagnosed in women because pregnancy-related LDL increases can obscure the underlying pattern, and postpartum lipid panels are rarely ordered. Women with FH who progress to Repatha use are disproportionately over 50, which places them in the higher-risk B12 group by age alone.

PCOS With Insulin Resistance

As described above, the metformin-PCOS-Repatha constellation is clinically real. Women with PCOS who develop frank type 2 diabetes and then ASCVD may accumulate decades of metformin use before anyone checks their B12. The Endocrine Society's PCOS guideline recommends metformin as a first-line insulin sensitizer, and cardiologists should be aware that long-term metformin users need periodic B12 monitoring when they inherit these patients later in the disease course.

Thyroid Disease and Cardiometabolic Risk

Hypothyroidism raises LDL-C through decreased LDL receptor expression. Women with untreated or undertreated hypothyroidism may present with apparent hypercholesterolemia that resolves with levothyroxine. If thyroid-related LDL elevation persists after optimization, statins and occasionally PCSK9 inhibitors are added. Women with autoimmune thyroid disease also have higher rates of autoimmune gastritis and pernicious anemia, a direct cause of B12 deficiency. This autoimmune intersection means a thyroid patient on Repatha has a credible independent reason to check B12.

What to Tell Your Clinician at Your Next Visit

Concrete talking points make visits more efficient. If you take Repatha and are considering or already using B12:

• "I take [dose] of B12 daily. Is there any reason to stop or adjust it given my Repatha?"
• "I also take metformin. Has my B12 been checked recently?"
• "I am postmenopausal and on a PPI. Can we add a serum B12 and MMA to my next labs?"
• "I am planning a pregnancy. When do I need to stop Repatha, and should I start a prenatal with B12 now?"

Your clinician should confirm that no interaction exists, reassure you that B12 supplementation at standard doses is appropriate, and schedule B12 monitoring if you fall into a higher-risk group.

Who This Approach Is Right For, and Who Should Be Cautious

Right for you if:

• You take Repatha and want to add a daily B12 supplement for general nutrition or because you are vegan or vegetarian.
• You are on metformin and Repatha and want to prevent neuropathy from B12 depletion.
• You are a postmenopausal woman with low dietary B12 intake who wants a simple nutritional buffer.

Needs more careful evaluation if:

• You have known pernicious anemia. Oral B12 alone may not be sufficient; your prescriber may recommend intramuscular dosing.
• You have had bariatric surgery. Absorption of oral cyanocobalamin may be unreliable, and higher doses or different routes may be needed.
• You are pregnant. Do not take Repatha. Continue or start B12 via a prenatal vitamin.

Not the right focus if:

• You are asking because you heard B12 "interacts" with cholesterol medications as a class. It does not, and the question is specifically about metformin-driven depletion in women who take multiple agents concurrently.